Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Shares Outstanding (Weighted Average): 2023-2025

Historic Shares Outstanding (Weighted Average) for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $87.0 million.

  • Immunome's Shares Outstanding (Weighted Average) rose 44.94% to $87.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.0 million, marking a year-over-year increase of 44.94%. This contributed to the annual value of $62.4 million for FY2024, which is 46.07% up from last year.
  • According to the latest figures from Q3 2025, Immunome's Shares Outstanding (Weighted Average) is $87.0 million, which was up 0.04% from $87.0 million recorded in Q2 2025.
  • Immunome's Shares Outstanding (Weighted Average)'s 5-year high stood at $87.0 million during Q3 2025, with a 5-year trough of $12.2 million in Q3 2023.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $60.0 million (2024), whereas its average is $53.0 million.
  • Data for Immunome's Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 392.15% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Immunome's Shares Outstanding (Weighted Average) stood at $42.7 million in 2023, then spiked by 46.07% to $62.4 million in 2024, then spiked by 44.94% to $87.0 million in 2025.
  • Its last three reported values are $87.0 million in Q3 2025, $87.0 million for Q2 2025, and $87.0 million during Q1 2025.